Show simple item record

dc.contributor.authorBastard, M*
dc.contributor.authorMolfino, L*
dc.contributor.authorMutaquiha, C*
dc.contributor.authorGalindo, MA*
dc.contributor.authorZindoga, P*
dc.contributor.authorVaz, D*
dc.contributor.authorMahinca, I*
dc.contributor.authordu Cros, P*
dc.contributor.authorRusch, B*
dc.contributor.authorTelnov, A*
dc.date.accessioned2019-04-19T18:58:52Z
dc.date.available2019-04-19T18:58:52Z
dc.date.issued2019-03-11
dc.date.submitted2019-04-09
dc.identifier.urihttp://hdl.handle.net/10144/619370
dc.description.abstractBedaquiline was recommended by WHO as the preferred option in treatment of MDR-TB patients with long regimen. However, no recommendation was given for the short MDR-TB regimen. Data from our small cohort of patients who switched injectable dug to bedaquiline suggest that bedaquiline based short regimen is effective and safe.en_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.rightsWith thanks to Oxford University Press.en_US
dc.titleTreatment outcomes of patients switching from an injectable drug to bedaquiline during short standardized MDR-TB treatment in Mozambiqueen_US
dc.identifier.journalClinical Infectious Diseasesen_US
refterms.dateFOA2019-04-19T18:58:52Z


Files in this item

Thumbnail
Name:
Bastard et al - 2019 - Treatment ...
Size:
437.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record